Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00344513
Status:
COMPLETED
Last Update Posted:
2020-11-24
First Post:
2006-06-23
Brief Title:
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure OPTIMIZE-HF
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure OPTIMIZE-HF An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic pathophysiologic clinical treatment and outcome characteristics of patients hospitalized with heart failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None